Literature DB >> 18256358

Survival in bladder and renal cell cancers is familial.

Jianguang Ji1, Asta Försti, Jan Sundquist, Per Lenner, Kari Hemminki.   

Abstract

Having family members with cancer has been associated with increased risk for bladder and renal cell cancers, but its association with survival has not been examined. This study was an analysis of the nationwide Swedish Family-Cancer Database and revealed that survival for bladder and renal cell cancers was similar whether the cancer was familial or sporadic; however, when survival in offspring was analyzed according to the affected parents' length of survival, prognosis was concordant. Cox proportional hazard regression models revealed that for bladder cancer, the risk for death among offspring whose parents survived > or =5 yr was approximately one third that of offspring whose parents survived <5 yr, after adjustment for gender, age at diagnosis, time period of diagnosis, socioeconomic status, and geographic region (adjusted hazard ratio 0.34; 95% confidence interval 0.15 to 0.80, for overall mortality). A risk of similar magnitude was found for renal cell cancer (adjusted hazard ratio 0.38; 95% confidence interval 0.16 to 0.87, for overall mortality). These population-level findings suggest heritability of prognosis for bladder and renal cell cancers. Genetic factors likely contribute to the mechanism underlying this observation.

Entities:  

Mesh:

Year:  2008        PMID: 18256358      PMCID: PMC2386727          DOI: 10.1681/ASN.2007070818

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  23 in total

1.  Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

Authors:  Tomonori Habuchi; Michael Marberger; Michael J Droller; George P Hemstreet; H Barton Grossman; Jack A Schalken; Bernd J Schmitz-Dräger; William M Murphy; Aldo V Bono; Peter Goebell; Robert H Getzenberg; Stefan H Hautmann; Edward Messing; Yves Fradet; Vinata B Lokeshwar
Journal:  Urology       Date:  2005-12       Impact factor: 2.649

Review 2.  Bladder cancer.

Authors:  Lester S Borden; Peter E Clark; M Craig Hall
Journal:  Curr Opin Oncol       Date:  2005-05       Impact factor: 3.645

3.  Familial papillary renal cell tumors and subsequent cancers: a nationwide epidemiological study from Sweden.

Authors:  Kamila Czene; Kari Hemminki
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

4.  Familial bladder cancer in the National Swedish Family Cancer Database.

Authors:  K Plna; K Hemminki
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

Review 5.  Genetic Epidemiology--science and ethics on familial cancers.

Authors:  K Hemminki
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

6.  Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Authors:  Robert F Ozols; Roy S Herbst; Yolonda L Colson; Julie Gralow; James Bonner; Walter J Curran; Burton L Eisenberg; Patricia A Ganz; Barnett S Kramer; Mark G Kris; Maurie Markman; Robert J Mayer; Derek Raghavan; Gregory H Reaman; Raymond Sawaya; Richard L Schilsky; Lynn M Schuchter; John W Sweetenham; Linda T Vahdat; Rodger J Winn
Journal:  J Clin Oncol       Date:  2006-12-08       Impact factor: 44.544

7.  Kidney cancer in the Swedish Family Cancer Database: familial risks and second primary malignancies.

Authors:  Kamila Czene; Kari Hemminki
Journal:  Kidney Int       Date:  2002-05       Impact factor: 10.612

8.  The nation-wide Swedish family-cancer database--updated structure and familial rates.

Authors:  K Hemminki; X Li; K Plna; C Granström; P Vaittinen
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

9.  The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence.

Authors:  Kari Hemminki; Charlotta Granström; Jan Sundquist; Justo Lorenzo Bermejo
Journal:  Hered Cancer Clin Pract       Date:  2006-12-15       Impact factor: 2.857

Review 10.  Epidemiology of urinary bladder cancer: from tumor development to patient's death.

Authors:  Cristiane Murta-Nascimento; Bernd J Schmitz-Dräger; Maurice P Zeegers; Gunnar Steineck; Manolis Kogevinas; Francisco X Real; Núria Malats
Journal:  World J Urol       Date:  2007-06       Impact factor: 3.661

View more
  7 in total

Review 1.  Genetic insights into the morass of metastatic heterogeneity.

Authors:  Kent W Hunter; Ruhul Amin; Sarah Deasy; Ngoc-Han Ha; Lalage Wakefield
Journal:  Nat Rev Cancer       Date:  2018-02-09       Impact factor: 60.716

Review 2.  A systems biology approach to defining metastatic biomarkers and signaling pathways.

Authors:  Natalie E Goldberger; Kent W Hunter
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2009 Jul-Aug

3.  Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer.

Authors:  Rebecca Brooks; Nora Kizer; Loan Nguyen; Atthapon Jaishuen; Karolyn Wanat; Elizabeth Nugent; Perry Grigsby; Jenifer E Allsworth; Janet S Rader
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

4.  Survival in non-Hodgkin's lymphoma by histology and family history.

Authors:  Jianguang Ji; Asta Försti; Jan Sundquist; Per Lenner; Kari Hemminki
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-17       Impact factor: 4.553

Review 5.  The role of individual inheritance in tumor progression and metastasis.

Authors:  Kent Hunter
Journal:  J Mol Med (Berl)       Date:  2015-06-10       Impact factor: 4.599

6.  The prognostic value of family history among patients with urinary bladder cancer.

Authors:  Lieke Egbers; Anne J Grotenhuis; Katja K Aben; J Alfred Witjes; Lambertus A Kiemeney; Sita H Vermeulen
Journal:  Int J Cancer       Date:  2014-07-09       Impact factor: 7.396

7.  Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study.

Authors:  Szu-Min Hsieh; Maxime P Look; Anieta M Sieuwerts; John A Foekens; Kent W Hunter
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.